Strategies to mitigate hypoglycemia and glycemic variability
DOI:
https://doi.org/10.47196/diab.v56i2Sup.533Keywords:
continuous glucose monitoring, ambulatory glucose monitoring, hypoglycemiaAbstract
The last decade has been highlighted by important advances in the development of new technologies for patients living with diabetes. The innovations have been oriented above all to improve the quality of life, reduce the impact generated by the occurrence of hypoglycemia and reduce the burden of the disease by collaborating in daily decision-making1.
Continuous glucose monitoring (CGM) is a tool that has undergone significant progress, providing dynamic information on the metabolic status of patients, allowing decision making, demonstrated by stable metabolic control, lower glycemic excursions and a significant reduction in the occurrence and severity of hypoglycemia2-5.
The purpose of these recommendations, developed by members of the Innovation Committee of the Argentine Society of Diabetes, is to provide rapid tools for the interpretation of metabolic data and the subsequent therapeutic decisionmaking. To this end, an exhaustive review of the main current guidelines and recommendations has been carried out, later the working group adapted this information according to a series of questions with practical clinical criteria.
The progress of CGMs is undeniable, not only in technological development, but it has become an educational tool for people with diabetes, their environment, and the health team, offering the possibility of a dynamic adjustment of treatment, prevention of acute complications and improving quality of life.
In this equation, we emphasize the importance of continuous diabetes education for the person with diabetes and their environment, actively participating in decision-making, and in this way, meeting the proposed objectives: improving quality of life, reducing the burden of disease, and decreasing acute glycemic excursions.
References
I. Prahalad P, Tanenbaum M, Hood K, Maahs DM. Diabetes technology: improving care, improving patient-reported outcomes and preventing complications in young people with type 1 diabetes. Diabetic Medicine 2018;35(4):419-429.
II. Choudhary P, Campbell F, Joule N, Kar P. A Type 1 diabetes technology pathway: consensus statement for the use of technology in type 1 diabetes. Diabet Med. 2019;36(5):531-583.
III. Reznik Y. Handbook of diabetes technology. Handb Diabetes Technol 2019;1-117.
IV. Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus. Diabetic Medicine 2021;38(5):e14528.
V. Lee I, Probst D, Klonoff D, Sode K. Continuous glucose monitoring systems. Current status and future perspectives of the flagship technologies in biosensor research. Biosens Bioelectron 2021;181-113054.
VI. NICE[NG17]. Type 1 diabetes in adults: diagnosis and management (NICE guideline). NICE Guidel. 2015. Disponible en: www.nice.org.uk/guidance/ng17.
VII. Balijepalli C, Druyts E, Siliman G, Joffres M, Thorlund K, Mills EJ. Hypoglycemia: A review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. Clinical Epidemiology 2017;9:291-296.
VIII. Jacob P, Chandran SR, Choudhary P. Treatment of type 1 diabetes complicated by problematic hypoglycemia. In: Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas 2019;1.
IX. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, De Vries JH, et al. International Consensus on use of continuous glucose monitoring. Diabetes Care 2017 Dec1;40(12):1631. Disponible en: http://care.diabetesjournals.org/content/40/12/1631.abstract.
X. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care 2019; 42(8):1593-1603.
XI. American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. Diabetes Technology: standards of medical care in diabetes 2022. Diabetes Care 2022;45(Suppl 1):S97-S112.
XII. Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract 2021;27(6):505-537.
XIII. Mechanick JI, Pessah-Pollack R, Camacho P, Correa R, Kathleen Figaro M, Garber JR, et al. American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists - 2017 update. Endocrine Practice 2017;23(8):1006-1021.
XIV. Aleppo G, Webb K. Continuous glucose monitoring integration in clinical practice: a stepped guide to data review and interpretation. J Diabetes Sci Technol 2019;13(4):664-673
XV. Kröger J, Reichel A, Siegmund T, Ziegler R. Clinical recommendations for the use of the ambulatory glucose profile in diabetes care. J Diabetes Sci Technol 2019;14(3):586-594.
XVI. Unnikrishnan AG, Saboo B, Joshi S, Kesavadev J, Makkar BM, Agarwal S, et al. Consensus statement on use of ambulatory glucose profile in patients with type 2 diabetes mellitus receiving oral antidiabetic drugs. J Assoc Physicians India 2019;67(11):76-83.
XVII. Litwak L, Carreño N, Carnero R, Dain A, Grosembacher L, Musso C, et al. Monitoreo continuo de glucosa: indicaciones, interpretación de datos y toma de decisiones terapéuticas. Rev Soc Arg Diab 2020;54(3).
XVIII. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The ambulatory glucose profile. Diabetes Technil Ther 2013;15(3):198-211.
XIX. Kalra S, Shaikh S, Priya G, Baruah MP, Verma A, Das AK, et al. Individualizing time-in-range goals in management of diabetes mellitus and role of insulin: clinical insights from a multinational panel. Diabetes Therapy 2021;12:465-485.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
